← Back to Search

Hormone Therapy

Hormone Therapy + Radiation for Prostate Cancer (PCS III Trial)

Phase 3
Waitlist Available
Led By Abdenour Nabid, MD
Research Sponsored by Abdenour Nabid
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 years
Awards & highlights

Summary

This trial would compare the results of two different doses of radiation therapy, given with or without hormone therapy, in order to determine which is more effective in reducing local failure rates.

Who is the study for?
Men with intermediate-risk prostate cancer, specifically untreated stage T1 or T2 adenocarcinoma of the prostate. Participants must have a Gleason score ≤7 and PSA levels within certain ranges. They should be disease-free from other cancers for over five years, able to attend treatments and follow-ups, and not have severe liver issues or medical/psychiatric conditions that could affect compliance.Check my eligibility
What is being tested?
The study is testing if six months of hormonal therapy (androgen blockade) can improve outcomes when combined with radiation therapy at two different doses (70 Gy and 76 Gy). It aims to see if hormonal treatment can reduce local failure rates like increasing radiation dose does, potentially offering more treatment options.See study design
What are the potential side effects?
Possible side effects include those related to hormone therapy such as fatigue, hot flashes, reduced sexual function, and potential bone thinning. Radiation may cause urinary symptoms like frequency or discomfort, bowel changes such as diarrhea, skin irritation in the treated area.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Interval before biochemical failure
Secondary outcome measures
Survival
Toxicity of irradiation

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Arm 2Experimental Treatment2 Interventions
Androgen blockade for 6 months + Radiotherapy 76 Gy
Group II: Arm 1Experimental Treatment2 Interventions
Androgen blockade for 6 months + Radiotherapy 70 Gy
Group III: Arm 3Active Control1 Intervention
Radiotherapy alone with 76 Gy

Find a Location

Who is running the clinical trial?

Abdenour NabidLead Sponsor
AstraZenecaIndustry Sponsor
4,302 Previous Clinical Trials
288,623,999 Total Patients Enrolled
59 Trials studying Prostate Cancer
26,922 Patients Enrolled for Prostate Cancer
Abdenour Nabid, MDPrincipal InvestigatorCRC - CHUS
1 Previous Clinical Trials
630 Total Patients Enrolled
1 Trials studying Prostate Cancer
630 Patients Enrolled for Prostate Cancer

Media Library

Androgen Blockade (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00223145 — Phase 3
Prostate Cancer Research Study Groups: Arm 1, Arm 3, Arm 2
Prostate Cancer Clinical Trial 2023: Androgen Blockade Highlights & Side Effects. Trial Name: NCT00223145 — Phase 3
Androgen Blockade (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00223145 — Phase 3
~24 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top